Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fampridine-SR for Visual Function in Poorly Recovered Optic Neuritis
NCT04148781Phase 1Unknown
- Start
- Mar 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dalfampridine in optic neuritis (ON). Primary endpoints: Change in Visual Evoked Potentials at 12 weeks, Change in Visual Acuity at 12 weeks and 5 more. Status: unknown.
02
Drugs
dalfampridine
03
Conditions
optic neuritis (ON)
Beyond the preview
Go deeper on NCT04148781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04148781.